Genetics of myeloproliferative neoplasms Journal Article


Authors: Viny, A. D.; Levine, R. L.
Article Title: Genetics of myeloproliferative neoplasms
Abstract: In the last decade, genomic studies have identified multiple recurrent somatic mutations in myeloproliferative neoplasms (MPNs). Beginning with the discovery of the JAK2 V617F mutation, multiple additional mutations have been found that constitutively activate cell-signaling pathways, including MPL, CBL, and LNK. Furthermore, several classes of epigenetic modifiers have also been identified, in patients with MPN, revealing a requirement for mutations in other pathways to cooperate with JAK-STAT pathway mutations in MPN pathogenesis. Mutations in the de novo DNA methylation protein, DNMT3A, demethylation machinery, TET2 and related IDH1/2 production of oncometabolite 2-hydroxygluterate, and polycomb complex proteins EZH2 and ASXL1 have opened new pathophysiologic clues into these diseases. The prognostic relevance of these novel disease alleles remains an important area of investigation, and clinical trials are currently underway to determine if these findings represent tractable therapeutic targets, either alone, or in combination with JAK2 inhibition.
Keywords: tyrosine kinase jak2; polycythemia-vera; essential thrombocythemia; chronic myelomonocytic leukemia; genomics; chronic; myelogenous leukemia; acute myeloid-leukemia; jak2; myeloproliferative neoplasms; cytogenetic responses; jak2 exon-12 mutations; asxl1 mutations; myelodysplastic/myeloproliferative neoplasms; v617f mutations
Journal Title: The Cancer Journal
Volume: 20
Issue: 1
ISSN: 1528-9117
Publisher: Lippincott Williams & Wilkins  
Date Published: 2014-01-01
Start Page: 61
End Page: 65
Language: English
ACCESSION: WOS:000337687700011
PROVIDER: wos
PMCID: PMC3898518
PUBMED: 24445766
DOI: 10.1097/PPO.0000000000000013
Notes: Review -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ross Levine
    775 Levine
  2. Aaron David Viny
    50 Viny